Observational studyMedicine2025
Thrombotic complications in critically ill patients with coronavirus infections: A comparative study of MERS and COVID-19.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronaviruses include coronavirus disease 2019 (COVID-19) and Middle East respiratory syndrome (MERS). These viruses cause respiratory infections in humans and share several overlapping structural, pathological, and genetic features. This study compared arterial and venous thrombotic events in critically ill patients with COVID-19 and MERS. This study was conducted in the intensive care units of 2 hospitals in Saudi Arabia. Polymerase chain reaction-positive patients who were diagnosed with COVID-19 between February and July 2020 and polymerase chain reaction-positive patients with MERS from March to May 2014 were included. The data were analyzed via SAS version 9.4 (SAS Institute, Cary, NC). This study included 294 patients, 234 (79.6%) of whom had COVID-19, and 60 (20.4%) had MERS. Overall, the rate of composite thrombotic events was 44 (14.97%) in both groups, comprising 25 patients with venous thromboembolism (23 patients with COVID-19 and 2 in the MERS group) and 19 with arterial thrombotic episodes (14 patients with COVID-19 and 5 in the MERS group). Bronchial asthma was significantly associated with thrombosis (P = .02). Enoxaparin was the most frequently prescribed thromboprophylaxis 189 (64.5%). There was no significant difference in venous thromboembolism (P = .10), bleeding complications (P = .53), or mortality (P = .08) between the COVID-19 and MERS patients. We found a similar rate of composite thrombotic events in critically ill patients with COVID-19 and MERS. While the thrombotic tendency of patients with COVID-19 was previously known, we uniquely identified the role of MERS in both arterial and venous thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.